-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple sclerosis (MS) is a disease that affects the central nervous system, making it difficult for the brain to send signals to the rest of the body
.
It can cause problems with vision, arm or leg movement and balance, which can eventually lead to severe disability
The three-and-a-half-year open-label extension study of ALITHIOS with 1,969 patients provided strong evidence for the continued safety of Kesimpta in the long-term treatment of MS
.
Results showed that nearly 2,000 patients tolerated the therapy well, with no new safety risks and no opportunistic infections
Nearly 2,000 patients tolerated the therapy well, with no new safety risks and no opportunistic infections
immunity
Lykke Hinsch Gylvin of Novartis explained: "While the low serum immunoglobulin observed with anti-CD20 therapy has historically been associated with an increased risk of serious infection, the immunoglobulin data on long-term exposure to Kesimpta show that this level remains at The overall incidence of severe cases, including COVID-19, was low within the reference range
.
These data give MS patients and their physicians confidence and further support Kesimpta as a potential preferred treatment option for MS
Previous studies demonstrated that MS patients taking Kesimpta had a significantly lower risk of relapse compared to teriflunomide
Original source:
Original source:https:// href="https://" target="_blank" rel="noopener">https:// https:// Leave a comment here
